Immune booster shows promise for bipolar depression
NCT ID NCT04133233
First seen Apr 24, 2026 · Last updated Apr 24, 2026
Summary
This study tested a low dose of interleukin-2 (IL-2) in 14 people with bipolar disorder who were currently depressed. The goal was to see if the treatment could increase certain immune cells (Tregs) and improve mood. Participants continued their usual mood stabilizers or antidepressants while receiving the study drug. The results focused on changes in immune response and depression scores.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIPOLAR DEPRESSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pr Marion Leboyer
Créteil, Hôpital Albert Chenevier, 94010, France
Conditions
Explore the condition pages connected to this study.